364779-15-7
基本信息
人參皂苷 RK3
人參皂苷RK3對(duì)照品
人參皂苷RK3(標(biāo)準(zhǔn)品)
人參皂苷RK3,R1=葡萄糖
人參皂苷RK3(人參皂甙RK3)
Ginsenoside Rk3 standard
β-D-Glucopyranoside, (3β,6α,12β)-3,12-dihydroxydammara-20,24-dien-6-yl
物理化學(xué)性質(zhì)
應(yīng)用領(lǐng)域
藥理藥效:可能有心血管、按腫瘤方面的活性
常見問題列表
NF-κB 14.24 μM (IC 50 , in HepG2 cells) |
NF-κB 15.32 μM (IC 50 , in SK-Hep1 cell) |
Ginsenoside Rk3 exerts the strong activity inhibiting NF-κB in a dose-dependent manner. HepG2 cells are pre-treated with different ginsenosides at concentrations ranging from 0.01 to 10 μM for 1 h, and induced with TNF-α for 20 h. Ginsenoside Rk3 significantly inhibits TNF-α-induced NF-κB transcriptional activity, with an IC 50 of 14.24±1.30 μM. Ginsenoside Rk3 significantly inhibits TNF-α-induced NF-κB transcriptional activity, with an IC 50 of 15.32±0.29 μM in SK-Hep1 cells, consistent with the data from HepG2 cells. Consistent with the inhibition of NF-κB, Ginsenoside Rk3 inhibits the induction of IL8 , CXCL1 , iNOS , and ICAM1 mRNA significantly in a dose-dependent manner.
The inhibitory effects of Ginsenoside Rk3 (Rk3) on tumor progression are studied in vivo using a H460 xenograft model in nude mice. Compared with the control group, a significant inhibition of tumor growth (volume) is observed in the Ginsenoside Rk3-treated group. Twenty-one days after treatment initiation, tumor growth is significantly inhibited by approximately 62.99% in the mice receiving 20 mg/kg Ginsenoside Rk3, similar to the inhibitory effect observed in the 20 mg/kg Gefitinib-treated group (57.21%). Compared with the control group, tumor growth is moderately inhibited in the mice receiving 10 and 5 mg/kg Ginsenoside Rk3, with inhibition rates of 32.54% and 11.84%, respectively.